Vigil Neuroscience (NASDAQ:VIGL) Rating Reiterated by JMP Securities

Vigil Neuroscience (NASDAQ:VIGL)‘s stock had its “market outperform” rating reaffirmed by equities research analysts at JMP Securities in a report issued on Thursday, Benzinga reports. They presently have a $23.00 target price on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $24.00 price target on shares of Vigil Neuroscience in a research note on Wednesday, March 27th.

Vigil Neuroscience Stock Up 2.5 %

VIGL stock opened at $2.82 on Thursday. Vigil Neuroscience has a twelve month low of $2.53 and a twelve month high of $11.11. The company has a market cap of $104.00 million, a PE ratio of -1.32 and a beta of 1.77. The business’s 50-day simple moving average is $3.16 and its 200 day simple moving average is $4.01.

Vigil Neuroscience (NASDAQ:VIGL) last released its earnings results on Tuesday, March 26th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.01). On average, equities research analysts anticipate that Vigil Neuroscience will post -2.56 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. PEAK6 Investments LLC raised its stake in shares of Vigil Neuroscience by 66.0% in the third quarter. PEAK6 Investments LLC now owns 23,796 shares of the company’s stock valued at $128,000 after acquiring an additional 9,459 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Vigil Neuroscience in the fourth quarter valued at approximately $124,000. JPMorgan Chase & Co. bought a new position in Vigil Neuroscience in the 2nd quarter worth approximately $120,000. Morgan Stanley raised its position in Vigil Neuroscience by 6,893.8% in the 4th quarter. Morgan Stanley now owns 9,092 shares of the company’s stock worth $114,000 after purchasing an additional 8,962 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Vigil Neuroscience by 87.1% in the 2nd quarter. Renaissance Technologies LLC now owns 37,488 shares of the company’s stock worth $97,000 after purchasing an additional 17,447 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.